MedTrace Logo

Efficacy of Songling Xuemaikang Capsules on Grade 1 Hypertension: a Randomized Controlled Trial

NCT06093932 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2024-08-20

No results posted yet for this study

Summary

The purpose of this study is:

1. To evaluate the efficacy of Songling Xuemaikang Capsules(SLXMKC) with grade 1 hypertension.
2. To reveal the potiential effects of SLXMKC on vascular function and structure of patients with grade 1 hypertension.
3. To explore the underlying mechanisms of the therapeutic effects of SLXMKC on the intervention of grade 1 hypertension.

Conditions

  • Hypertension,Essential

Interventions

DRUG

Songling Xuemaikang Capsules

3 capsules at a time, three times a day, duration: 12 weeks

BEHAVIORAL

Lifestyle intervention

everyday, duration: 12 weeks

DRUG

Placebo

3 capsules at a time, three times a day, duration: 12 weeks

Sponsors & Collaborators

  • China Academy of Chinese Medical Sciences Xiyuan Hospital Shanxi Hospital

    collaborator UNKNOWN

  • Suzhou Hosptial of Traditional Chinese Medicine

    collaborator UNKNOWN

  • China Academy of Chinese Medical Sciences Xiyuan Hospital Jining Hospital

    collaborator UNKNOWN

  • Shandong University of Traditional Chinese Medicine

    collaborator OTHER

  • Xiyuan Hospital of China Academy of Chinese Medical Sciences

    lead OTHER

Principal Investigators

  • Hao Xu, Prof. · Xiyuan Hospital of China Academy of Chinese Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-07
Primary Completion
2024-12-31
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06093932 on ClinicalTrials.gov